Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TENX with free AI briefings, catalyst countdowns, and dilution alerts.

TENX · TENAX THERAPEUTICS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$113.7M Cash on Hand
25.6mo Cash Runway
Follow TENX by email Get an email when TENX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TENX, unsubscribe in one click. Privacy

📣 What TENX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Levosimendan Coronary Artery Bypass Grafting Phase 3 · NCT02025621 Completed
TNX-103 Pulmonary Hypertension Phase 3 · NCT05983250 Active not recruiting
Oxycyte Traumatic Brain Injury Phase 2 · NCT00174980 Terminated

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TENX holds $113.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $13.3M/quarter from operations, an estimated runway of 25.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TENX files for a raise →

👥 Who Owns TENX

Insiders 21.9% Other 5%+ holders 13.4% Institutions (154 holders) 64.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
ADAR1 Capital Management, LLC
10% owner
Insider 7,447,000 16.35% 2026-10-19
Vivo Opportunity Fund Holdings, L.P. 5%+ holder (13G) 3,458,327 7.59% 2026-06-30
BVF PARTNERS L P/IL Institution (13G, 5%+) 3,110,363 6.83% 2026-06-30
RTW Investments, LP Institution (13G, 5%+) 2,866,654 6.30% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 2,804,788 6.16% 2026-09-30
Sphera Funds Management Ltd. 5%+ holder (13G) 2,663,296 5.85% 2026-09-30
Dellora Investments LP
no longer 10% owner
Insider 2,400,000 5.27% 2026-10-02
Declan Doogan
Director · +210,012 options
Insider 55,274 0.12% 2026-09-16
Christopher Thomas Giordano
CEO, Director · +3.09M options
Insider 22,174 0.05% 2026-09-11
Thomas R Ii Staab
Chief Financial Officer · +450,000 options
Insider 15,675 0.03% 2026-09-11
Stuart Rich
Chief Medical Officer, Director · +2.00M options
Insider 12,654 0.03% 2026-01-09
Thomas Mcgauley
Interim CFO · +50,000 options
Insider 8,000 0.02% 2026-01-30

Share count 45,536,448 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TENX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TENX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.